Crossmark

: K.K., Ma.M., A.M.G.-A., J.A.B., P.R.C., K.G., Y.-M.Y., M.A., and Me.M. were responsible for this study design and developed the research strategy. K. K. and Ma.M. managed the distribution of questionnaires to the participating countries. K.K., N.W., J.L., and T.W. performed the data extraction. K.K., Ma.M., P.S., N.W., T.P., and N.A. performed the formal analyses. K.K., Ma.M., T.Z., L.C., and C.K. prepared the visualization. K.K., Ma.M., T.Z., J.A.B., M.R., P.S., P.K., C.K., L.C., N.W., T.P., N.A., and J.L. wrote the first draft of the manuscript. K.K., T.Z., J.L., and T.W. prepared a graphical abstract. All investigators contributed to the study recruitment, data acquisition, manuscript editing, and review of the final submitted version. All authors had full access to the data, accept responsibility for the decision to submit for publication, and have read and approved the final version of the manuscript.

: The study was conducted independently, with no funding source influencing its design, data collection, analysis, interpretation, or manuscript preparation. The publication of this paper was supported by an unrestricted educational grant from the Global Allergy and Asthma Excellence Network.

: K.K. received educational speaker fees from Novartis, Menarini, Sanofi Genzyme and Takeda, outside of submitted work. J.A.B is or recently was a principal investigator and consultant of Sanofi-Regeneron, Novartis, Genentech, Teva, AZ, Amgen, Celldex, Jasper, Allakos, Blueprint Medicine, Escient/Incyte. M.A. is or recently was a speaker and advisory board honoraria from GSK, Sanofi, Novartis and AstraZeneca, outside of the submitted work. A.A. was a speaker for Novartis, outside of the submitted work. R.F.J.C. received fees for lectures or consulting outside of this article from the following laboratories: Pfizer, Sanofi, Novartis, Lilly. A.M.G.-A. is or recently was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Blueprint Medicines, Celldex, Escient Pharmaceuticals, Genentech, GSK, Harmonic Bio, Instituto Carlos III- FEDER, Jaspers, Leo Pharma, Menarini, Mitsubishi Tanabe Pharma, Noucor, Novartis, Sanofi–Regeneron, Septerna, Servier, Thermo Fisher Scientific, Uriach Pharma. M.H. has recently received lecture and/or consultation fees from Kaken Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis, Sanofi/Regeneron, Taiho Pharmaceutical, and Teikoku Seiyaku. N.I. is or recently was a speaker and/or has received research funding from GSK, Tanabe-Mitsubishi Pharma, Novartis, Sanofi–Regeneron, Taiho, Torii, and Kyowa-Kirin. M.K. was a speaker and/or advisor for and/or has received research funding from Abidi Pharma, Alhavi Pharma, AstraZeneca, Actoverco, Ofogh Tolid Darou Pars, Kimia Salamat Nikan, CinnaGen, Sanofi, GlaxoSmithKline and Danon, outside of the submitted work. P.K. was a speaker and/or consultant for BioCryst, Merus, Novartis and ValenzaBio, outside of the submitted work. Me.M. is or recently was a speaker, advisor and/or received research funding from Jasper Therapeutics, Celltrion, Celldex, Takeda, BioCryst, Annexon and Roche. R.Ö.K. was a speaker for Novartis, AbbVie, Lilly and La Roche–Posay. J.P. received lecture fees from Novartis, UCB, Ferrer and Viatri and participated in clinical trials from Almirall. P.T. received educational speaker fees from Novartis, Menarini, and Sanofi Genzyme outside of the submitted work. Ma.M. is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alexion, Alvotech, Almirall, Amgen, Aquestive, argenx, AstraZeneca, Celldex, Celltrion, Clinuvel, Escient, Evommune, Excellergy, GSK, Incyte, Jasper, Kashiv, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnology, Resoncance Medicine, Sanofi/Regeneron, Santa Ana Bio, Sep- terna, Servier, Third Harmonic Bio, ValenzaBio, Vitalli Bio, Yuhan Corporation, and Zurabio. T.Z. has received institutional funding for research and/or honoraria for lectures and/or consulting from Amgen, AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, Blueprint Medicines, FAES, HAL, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, and Uriach; in addition, he is a member of Allergic Rhinitis and its Impact on Asthma (ARIA), the German Society for Allergy and Clinical Immunology (DGAKI), the European Centre for Allergy Research Foundation (ECARF), the Global Allergy and Asthma European Network (GA 2 LEN) and World Allergy Organization (WAO). The other authors have no conflicts of interest to declare.

: The protocol was approved by the Siriraj Institutional Review Board (Si-137/2022), and local institutional review boards for sites not covered by this central institutional review board.

: Informed consent was obtained from all participants. At the end of the introduction part of the questionnaire, participants were asked to indicate their willingness to take part in the study and to complete the PREVALENCE-D questionnaire.

: Not applicable.

: The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in controlled access data storage in the Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Document is current

Any future updates will be listed below